Background
==========

Atrial fibrillation (AF), the most common sustained arrhythmia, has become one of the severe challenges in the field of global cardiovascular diseases, and can lead to many clinical complications such as stroke and heart failure \[[@b1-medscimonit-26-e918883]\]. Unfortunately, there is still no a comprehensive and clear understanding of the specific pathogenesis of AF. Clinical and experimental evidence suggest that fibrosis activates reentry circuits in the atrium by increasing inhomogeneous electrical conduction, which is considered to be a crucial contributor to AF \[[@b2-medscimonit-26-e918883]--[@b4-medscimonit-26-e918883]\].

Although the underlying pathophysiological mechanisms leading to cardiac fibrosis are complex, transforming growth factor-β1 (TGF-β1) has a close correlation with AF \[[@b1-medscimonit-26-e918883],[@b5-medscimonit-26-e918883]\]. In a variety of organ systems, such as lung, liver, and heart, TGF-β1 and its related factors are critical inflammatory, pro-fibrotic cytokines that contribute to the production of extracellular matrix, and the overproduction of extracellular matrix in atrial tissues indicates the formation of structural reconstruction \[[@b6-medscimonit-26-e918883],[@b7-medscimonit-26-e918883]\]. Indeed, the majority of experimental studies in animals have demonstrated that upregulated expression of TGF-β1 can lead to atrial-specific fibrosis and increase AF vulnerability \[[@b7-medscimonit-26-e918883],[@b8-medscimonit-26-e918883]\]. TGF-β1 regulates its effects via interactions of transmembrane type I receptor (TGF-βRI) and type II receptor (TGF-βRII). Once bound to TGF-β1, TGF-βRII recruits and phosphorylates TGF-βRI, and this triggers phosphorylation of Smads, which can then manipulate the expression of fibrosis marker proteins, including CTGF, α-SMA, and Collagen I \[[@b10-medscimonit-26-e918883]--[@b12-medscimonit-26-e918883]\]. A previous study \[[@b13-medscimonit-26-e918883]\] reported that miR-30c, an microRNA participating in the anti-fibrotic process, is a downstream factor of TGF-β1, and found that TGF-β1 can suppress miR-30c level, which in turn negatively regulates the expression of its target gene TGF-βRII and thereby amplifies the biological effects of the TGF-β1 signaling pathway.

Doxycycline (Doxy) is a long-acting semisynthetic tetracycline antibiotic clinically used for several decades to treat infectious diseases \[[@b14-medscimonit-26-e918883]\]. Besides its well-known anti-inflammatory properties, Doxy has been found to improve the fibrogenic response. Hua et al. \[[@b15-medscimonit-26-e918883]\] reported that Doxy can markedly improve pulmonary interstitial fibrosis induced by paraquat via inhibiting the TGF-β1 signal transduction pathway.

Recently, chronic intermittent hypoxia (CIH) has been frequently used to explore the pathogenesis of AF because of its role in causing atrial interstitial fibrosis \[[@b16-medscimonit-26-e918883],[@b17-medscimonit-26-e918883]\]. It has been unclear whether Doxy can also attenuate CIH-induced atrial interstitial fibrosis, atrial conduction, and AF susceptibility by interfering with TGF-β1 signaling pathway; therefore, we performed the present study to test this hypothesis by establishing a CIH-induced AF rat model.

Material and Methods
====================

Experimental animals and protocol
---------------------------------

This study was approved by the Experimental Animal Administration Committee of Tianjin Medical University.

Sixty Sprague-Dawley male rats (8 weeks old, weight 180--200 g), purchased from the BEIJING HFK BIOSCIENCE CO. (Beijing, China). Rats in the DOXY group were administered Doxy (30 mg/kg/d, according to animal pharmacology data) by oral gavage prior to exposure to CIH (6 h/d) for 6 consecutive weeks.

During the exposure periods, CIH and Doxy-treated rats were placed inside a plexiglas chamber connected to supplies of pure O~2~ and N~2~, which was applied to create the intermittent hypoxia condition. In the CIH protocol, the O~2~ concentration in the chamber was gradually reduced from 21% to 8% by flushing with 100% nitrogen for 160 s, held at 8% for 50 s, and then returned to 21% by flushing with O~2~ for 90 s. Each complete cycle lasted approximately 300 s, and the O~2~ concentration inside the chamber was alternately switched between 8% and 21%. Within 24 h after the last exposure, from each group, 10 rats were randomized to perform experiments including echocardiography, hemodynamic examination, and histological and molecular biological studies. The remaining 30 rats underwent isolated atrial epicardial activation mapping and heart electrophysiology.

Echocardiographic assessment
----------------------------

After 6 weeks of CIH, rats were anesthetized with isoflurane (1 L/min) and transthoracic echocardiography was performed. The interventricular septum thickness, left atrial diameter, left ventricular end-diastolic and end-systolic diameters, mean pulmonary artery pressure, and left ventricular ejection fraction were determined.

Hemodynamic assessment and sample collection
--------------------------------------------

After echocardiography, a Millar pressure cannula was carefully inserted into the right carotid artery to record the aortic systolic and diastolic blood pressure of rats. Subsequently, the rats were instantly euthanized and left atrial (LA) tissues were rapidly separated. Samples for histological assessment were soaked in neutral buffered 10% formalin solution, and samples for molecular biological experiments were quickly stored in a liquid nitrogen tank.

Histological studies
--------------------

5-micron tissue sections were collected and corresponding staining was performed. Masson's trichrome staining was used to estimate the extent of interstitial fibrosis. The left atrial interstitial collagen volume fraction (LACVF) was calculated as \[blue area/(red area+blue area)\]×100%. Immunohistochemistry staining was applied to identify the protein expression levels of TGF-β1 and related downstream factors, with the mean optical density (MOD) was defined as integral optical density (IOD)/the area of brown granules. Blood vessels were excluded from quantitative analysis.

Real-time PCR
-------------

For detection of mRNAs, 1 μg of total RNA extracted from LA was reverse transcribed into cDNA, after which relative quantification was conducted using the 7500 Real-Time PCR Detection System. For detection of miR-30c, the cDNA was added to a miR-30c stem-loop. The expression levels of mRNAs and miR-30c were normalized to GAPDH and U6, respectively. Data analysis was performed by 2^−ΔΔCt^ method and was repeated 3 times for each specimen. The primers used are shown in [Table 1](#t1-medscimonit-26-e918883){ref-type="table"}.

Western blotting
----------------

Total protein was extracted by RIPA lysis buffer (KeyGEN Biotech, Nanjing) and then underwent Western blot analysis, as described elsewhere \[[@b18-medscimonit-26-e918883]\]. β-actin served as the loading control.

Surface ECGs, isolated atrial epicardial activation mapping, and heart electrophysiology
----------------------------------------------------------------------------------------

The remaining 30 rats underwent isolated atrial epicardial activation mapping and heart electrophysiology assessment after surface ECGs. Briefly, the beating heart isolated from an anesthetized rat was carefully but rapidly removed and connected to a Langendorff perfusion system full of warmed Tyrode's solution (37°C) saturated with a mixture of 95% O~2~ and 5% CO~2~ gas mixture.

With the spontaneously and normally beating of heart, a 36-electrode microelectrode array arranged in a 6×6 configuration (PA03606060101, Multielectrode Probe array) was positioned on the epicardial surface of the left atrium for recording multiple activation signals. Activation waveforms acquired were amplified by a filter amplifier (EMS64-USB-1003, 64 channels) and transmitted to the connected computer. All activation times were digitized and then used to draw activation maps. The activation times were determined as the point of maximal negative slope of activation waveforms. Inhomogeneity index, absolute inhomogeneity, and conduction velocity were calculated using the Electric Mapping Scope System (MappingLab, UK).

At the end of activation mapping, 3 pairs of electrodes were connected to the epicardial surface of the high right atrium, high left atrium, and right ventricular apex, respectively. The atrial effective refractory period (AERP) and intermediary atrial conduction time (IACT) were measured by our electrophysiological recording and measurement program. AF vulnerability was evaluated by burst pacing for 3 s (10 times). The occurrence of AF was determined as rapid, irregular atrial, and ventricular responses lasting for more than 1000 ms. Between these stimulation procedures, there were 30-s recovery periods.

Statistical analysis
--------------------

All results are expressed as mean±SD and analyzed by one-way analysis of variance (ANOVA) after Bonferroni correction. SPSS 22.0 software was applied for data analysis. The statistically significant p value was set at 0.05.

Results
=======

Echocardiographic and hemodynamic characteristics
-------------------------------------------------

[Table 2](#t2-medscimonit-26-e918883){ref-type="table"} indicates the findings of transthoracic echocardiography and hemodynamics.

Compared with the Control group, mean pulmonary artery pressure (mPAP) was significantly increased in the CIH group (67.88±1.65 *vs.* 65.51±2.66, P \<0.05), which was improved by Doxy treatment, but the difference was not significant. No significant differences in LAD, LVESD, LVEDD, IVS, LVEF, heart weight ratio, and the hemodynamic parameters were observed among the 3 groups.

LA interstitial fibrosis
------------------------

[Figure 1](#f1-medscimonit-26-e918883){ref-type="fig"} showed an obvious broader geographic areas of atrial interstitial collagen deposition in the CIH group than in the Control group, which was markedly improved by Doxy treatment. Left atrial interstitial collagen volume fraction (LACVF) among the Control, CIH, and DOXY groups were 1.70±0.92%, 5.44±2.94%, and 2.85±1.72%, respectively (P\<0.01).

Comparison of immunohistochemistry
----------------------------------

The CIH group showed more positive particles deposition in left atrium than in the Control group in TGF-β1, TGF-βRII, p-Smad2/3, α-SMA, CTGF, and Collagen I. Similarly, the MOD of these factors were also prominently higher in the CIH group compared to the Control group, and these changes were mitigated by Doxy treatment ([Figure 2](#f2-medscimonit-26-e918883){ref-type="fig"}).

Expressions of TGFβ1 signaling factors and fibrosis marker proteins
-------------------------------------------------------------------

Compared to the Control rats, the CIH rats exhibited increased mRNA and protein expression levels of TGF-β1, TGF-βRI, TGF-βRII, and the ratio of the phosphorylated (p) form versus total (t) Smad2/3, and decreased expression level of miR-30c. These alterations were ameliorated in Doxy-treated rats ([Figures 3A--3D](#f3-medscimonit-26-e918883){ref-type="fig"}, [4A--4D](#f4-medscimonit-26-e918883){ref-type="fig"}). Similarly, we detected notably increased mRNA and protein expression levels of the fibrosis marker proteins CTGF, α-SMA, and Collagen I in the CIH group, and the expression levels of these factors were markedly ameliorated in the DOXY group ([Figures 3E--3G](#f3-medscimonit-26-e918883){ref-type="fig"}, [4E--4G](#f4-medscimonit-26-e918883){ref-type="fig"}).

Surface ECGs, electrophysiology, and activation mapping parameters
------------------------------------------------------------------

The specific values of the surface ECGs and isolated heart electrophysiological parameters are shown in [Table 3](#t3-medscimonit-26-e918883){ref-type="table"}. The Control group had a notable difference from the CIH group in P-wave duration (14.13±1.78 *vs.* 18.13±6.22, P\<0.05). Electrophysiological results exhibited longer inter-atrial conduction time (IACT) in the CIH group than in the Control group after pacing stimulation at basic cycle lengths of 150, 200, and 250 ms. These changes were clearly reversed by Doxy treatment. Representative diagrammatic sketch of AF induction was shown in [Figure 5G](#f5-medscimonit-26-e918883){ref-type="fig"}. Furthermore, the CIH group had a higher induction ratio of AF than in the Control group, and Doxy treatment greatly reduced the occurrence of AF. AF inducibility among the 3 groups was 21.00±15.95%, 35.00±12.69%, and 20.00±11.55%, respectively (P\<0.05) ([Figure 5H](#f5-medscimonit-26-e918883){ref-type="fig"}). However, other parameters from surface ECGs and isolated heart electrophysiology showed no statistically significant differences among the 3 groups.

Representative maps of three groups were shown in [Figure 5A--5C](#f5-medscimonit-26-e918883){ref-type="fig"}. Atrial activation mapping showed that, compared with the Control group, the atrial electrical conduction inhomogeneity index and absolute inhomogeneity were remarkably increased in the CIH group, whereas the mean conduction velocity was significantly decreased. These changes were improved by Doxy treatment ([Figures 5D--5F](#f5-medscimonit-26-e918883){ref-type="fig"}).

Discussion
==========

In this study, we assessed the protective functions of Doxy on atrial fibrosis, atrial conduction, and AF vulnerability using a CIH rat model. The main findings were: (1) 6 weeks of CIH can significantly increase LA interstitial fibrosis; (2) profoundly enhanced atrial fibrosis contributed to some electrophysiological abnormalities, including increased atrial electrical conduction inhomogeneity index, absolute inhomogeneity, inter-atrial conduction time, AF vulnerability, and decreased mean velocity of left atrial conduction; and (3) Doxy can significantly improve CIH-induced fibrosis and electrophysiological properties changes in atrium secondary to fibrosis via inhibition of the TGF-β1/Smad2/3 signaling pathway.

AF is a commonly encountered cardiac arrhythmia in clinical practice, with very high mortality and disability rates \[[@b19-medscimonit-26-e918883]\]. It is clear that atrial electrophysiological and structural alterations participate in the initiation and maintenance of AF \[[@b20-medscimonit-26-e918883],[@b21-medscimonit-26-e918883]\]. Of the atrial structural changes, fibrosis is regarded as particularly critical to creating the AF substrate, with fibrosis likely promoting the formation of intra-atrial reentry circuits by increasing non-uniform anisotropy and local electrical conduction heterogeneities \[[@b4-medscimonit-26-e918883],[@b22-medscimonit-26-e918883]\]. Our electrophysiological results demonstrated that severe interstitial fibrosis contributed to increased conduction inhomogeneity and decreased conduction velocity of the left atrium in CIH rats, and these changes are essential to the development and maintenance of atrial conduction reentry circuits and progression to AF.

P-wave indices such as duration, variance, and dispersion are reliable noninvasive marker of intra-atrial and inter-atrial conduction \[[@b23-medscimonit-26-e918883]\]. Previous studies \[[@b24-medscimonit-26-e918883],[@b25-medscimonit-26-e918883]\] demonstrated that prolonged P-wave duration is not a totally benign condition. Indeed, P-wave prolongation is an indicator of AF in patients after bypass surgery, and people with an prolonged P-wave duration are more likely to experience paroxysmal AF and progress toward persistent AF \[[@b26-medscimonit-26-e918883],[@b27-medscimonit-26-e918883]\]. We observed that CIH caused remarkably prolonged P-wave duration and some abnormalities in atrial conduction, as well as higher AF inducibility. These findings were similar to published results showing that P-wave prolongation might be a reliable indicator for AF incidence.

TGFβ1, a pro-fibrotic cytokine, has been proved to be involved in formation and deposition of extracellular matrix components, contributing to tissue and organ fibrosis \[[@b6-medscimonit-26-e918883]\]. Additionally, TGF-β1 a pivotal fibrotic signaling ligands in a number of different animal models of atrial remodeling established by rapid atrial pacing, angiotensin II stimulation, aortic constriction, and CIH \[[@b28-medscimonit-26-e918883]\]. When TGF-β1 binds to its heterodimeric receptor complex, TGF-βRI and TGF-βRII, the downstream canonical Smads signaling cascades are activated. The signaling molecules Smad2/3 are more dedicated downstream effectors of the classical TGF-β1 pathway in the initiation and progression of cardiac fibrosis \[[@b29-medscimonit-26-e918883]--[@b31-medscimonit-26-e918883]\]. Hence, we used Smad2/3 activation as an indicator of the TGF-β1 pathway. Our results indicated that activation of the TGF-β1/Smad2/3 pathway plays a critical role in CIH-induced atrial fibrosis and atrial conduction abnormalities caused by fibrosis, which might be the key molecular mechanism by which Doxy exerts a remarkable therapeutic efficacy on atrial interstitial fibrosis.

MicroRNAs (miRs) are small, endogenous, 20--23 nucleotide noncoding RNAs which can downregulate gene expression by combining with the 3′untranslated region of the target mRNA \[[@b32-medscimonit-26-e918883]\]. Recently, miRs were found to take part in many biological and disease processes, including fibrosis \[[@b33-medscimonit-26-e918883],[@b34-medscimonit-26-e918883]\]. miR-30c, identified as an anti-fibrotic microRNA, is involved in the atrial fibrogenic response. A recent study \[[@b13-medscimonit-26-e918883]\] showed that TGF-β1 can also mediate its pro-fibrotic function by repressing the expression level of miR-30c, which in turn upregulates the expression level of the target gene TGF-βRII and further amplifies the effects of the TGF-β1 pathway. In accordance with the above-mentioned study, the expression level of miR-30c was negatively related to TGF-β1 and was downregulated in our CIH rats, which was accompanied by a remarkably increased expression level of TGF-βRII.

Doxy, a major tetracycline antibiotic, is widely used in the treatment of infectious disorders in humans and animals. Recently, Doxy was found to have an anti-fibrotic role by reducing the production of extracellular matrix. As outlined above, Fujita et al. \[[@b35-medscimonit-26-e918883]\] indicated that Doxy significantly alleviated bleomycin-induced pulmonary interstitial fibrosis in mice. A related study \[[@b36-medscimonit-26-e918883]\] found that Doxy can also ameliorate cardiac fibrosis and hypertrophy caused by isoproterenol in rats. Moreover, Doxy was confirmed to reduce the production of matrix metalloprotein 9 by blocking upregulation of the TGF-β1/Smad pathway in human corneal epithelial cells \[[@b37-medscimonit-26-e918883]\].

In the present study, we found that atrial interstitial fibrosis can be alleviated by Doxy treatment in rats exposed to CIH for 6 weeks (5.44±2.94% *vs.* 2.85±1.72%). To further determine the specific molecular mechanisms by which Doxy interferes with the process of fibrogenesis, we assessed the expression levels of TGF-β1 pathway-related factors in our 3 groups, showing that the TGF-β1/Smad2/3 pathway was highly activated and the expression levels of its downstream fibrosis marker proteins were also significantly elevated in the CIH group; those changes were somewhat inhibited by Doxy treatment.

Our results show that the TGF-β1 pathway participates in the course of CIH-induced atrial interstitial fibrosis and is crucial in this pathological process. Doxy might be a promising drug for use in preventing and treating atrial fibrosis, as well as the consequent electrophysiological abnormalities by mediating the TGF-β1/Smad2/3 pathway. Further investigations are needed to better understand its beneficial effects on atrial remodeling.

Limitations
-----------

Firstly, we did not examine the serum levels of TGF-β1and fibrotic markers among the 3 groups, but the expression levels of those factors in atrial tissue should be more telling. Secondly, our experiment failed to directly validate the targeted relationships among TGF-β1, miR-30c, and TGF-βRII. However, relevant conclusions were verified by using neonatal cardiac fibroblasts separated from the atria of Sprague-Dawley rats, which is consistent with our animal species and organ specificity.

Conclusions
===========

Fibrosis-induced alternations in atrial conduction and AF susceptibility in CIH rats can be mitigated by Doxy, which was closely associated with the TGF-β1/Smad2/3 signaling pathway.
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![Representative photomicrographs of left atrial sections subjected to Masson's trichrome staining in three groups (original magnification ×400). Control group (**A**); CIH group (**B**); DOXY group (**C**); The illustration of the LACVF (**D**). \*\*\* p\<0.001 *vs.* Control(CON) group. ^\#\#^ p\<0.01 *vs.* CIH group. NS -- no significance.](medscimonit-26-e918883-g001){#f1-medscimonit-26-e918883}

![Mean optical density of target proteins (TGF-β1, TGF-βRI, TGF-βRII, Smad2/3, p-Smad2/3, α-SMA, CTGF, CollagenI) in three groups. \* p\<0.05, \*\* p\< 0.01 *vs.* Control (CON) group. ^\#^ p\<0.05 *vs.* CIH group.](medscimonit-26-e918883-g002){#f2-medscimonit-26-e918883}

![mRNA expression levels of TGF-β1 (**A**), miR-30c (**B**), TGF-βRI (**C**), TGF-βRII (**D**), α-SMA (**E**), CTGF (**F**), CollagenI (**G**) in three groups.\* p\<0.05, \*\* p\<0.01, and \*\*\* p\<0.001 *vs.* Control group (CON). ^\#^ p\<0.05, ^\#\#^ p\< 0.01, and ^\#\#\#^ p\< 0.001 *vs.* CIH group. NS -- no significance.](medscimonit-26-e918883-g003){#f3-medscimonit-26-e918883}

![Protein expression levels of TGF-β1 (**A**), TGF-βRI (**B**), TGF-βRII (**C**), p-Smad2/3 and Smad2/3 (**D**), α-SMA (**E**), CTGF (**F**), CollagenI (**G**) in three groups. \* p\<0.05, \*\* p\<0.01, and \*\*\* p\< 0.001 *vs.* Control group (CON). ^\#^ p\<0.05, ^\#\#^ p\<0.01, and ^\#\#\#^ p\<0.001 *vs.* CIH group. NS -- no significance.](medscimonit-26-e918883-g004){#f4-medscimonit-26-e918883}

![Abridged general view of atrial epicardial activation mapping and AF inducibility. Representative maps of spontaneous left atrial epicardial activation among Control (**A**), CIH (**B**) and DOXY group (**C**). From dark red to dark blue, scale bar indicates total time from first activated locus to last activated locus within one heartbeat. Comparison of inhomogeneity index in 3 groups (**D**). Comparison of absolute inhomogeneity between 3 groups (**E**). Comparison of mean conduction velocity in 3 groups (**F**). Representative diagrammatic sketch of AF induction (**G**). Comparison of AF inducibility in three groups (**H**). HRA -- high right atrium; HLA -- high left atrium; RV -- right ventricular. \* p\<0.05 *vs.* Control (CON) group. ^\#^ p\<0.05 *vs.* CIH group. NS -- no significance. n=10 per group.](medscimonit-26-e918883-g005){#f5-medscimonit-26-e918883}

###### 

Primers used for quantitative RT-PCR.

  Target gene                Primer sequence (5′-3′)                                       Tm (°C)
  -------------------------- ------------------------------------------------------------- ---------
  U6                         F: CTCGCTTCGGCAGCACA                                          56.00
  R: AACGCTTCACGAATTTGCGT    53.35                                                         
  miR-30c stem-loop          GTCGTATCCAGTGCGTGTCGTGGAGTCGGCAATTGCACTGGATACGACGACGAGAGTCG   77.61
  miR-30c forward primer     GCGGTGTAAACATCCTACA                                           56.00
  Universal reverse primer   GTATCCAGTGCAGGGTCCGAGGT                                       63.77
  GAPDH                      F: AGTGCCAGCCTCGTCTCATA                                       57.45
  R: ACCAGCTTCCCATTCTCAGC    57.45                                                         
  TGF-β1                     F: CGCTTCTGCTCCCACTCC                                         60.00
  R: TGTTGCGGTCCACCATTA      54.00                                                         
  TGF-βRI                    F: ACTTCCCAACTACAGAAAAGCA                                     56.00
  R: ATGACAGTGCGGTTATGGCA    56.00                                                         
  TGF-βRII                   F: CCCAAGTCGGTTAACAGCGAT                                      57.80
  R: TGGCAATGACAGCTATGGCA    55.40                                                         
  α-SMA                      F: GGAGATGGCGTGACTCACAA                                       57.45
  R: CGCTCAGCAGTAGTCACGAA    57.45                                                         
  CTGF                       F: CTTCCCGAGAAGGGTCAAGC                                       60.39
  R: TTCCAGTCGGTAGGCAGCTA    60.32                                                         
  CollagenI                  F: CCCAGCGGTGGTTATGACTT                                       57.45
  R: TCGATCCAGTACTCTCCGCT    57.45                                                         

Tm (°C) -- melting temperature; F -- forward; R -- reverse

###### 

Hemodynamic and echocardiographic studies.

  Data                          Control group(n=10)   CIH group(n=10)                                                     Doxy group (n=10)   P value
  ----------------------------- --------------------- ------------------------------------------------------------------- ------------------- ---------
  SBP, mm Hg                    147.9±19.7            163.7±15.7                                                          152.3±17.6          0.162
  DBP, mm Hg                    115.9±18.3            126.5±13.1                                                          120.7±16.3          0.342
  MBP, mm Hg                    131.6±18.4            144.2±13.4                                                          136.6±15.1          0.242
  Pulse Pressure, mm Hg         32.0±7.9              37.2±4.6                                                            31.6±6.8            0.169
  LAD (mm)                      3.63±0.33             3.85±0.20                                                           3.77±0.26           0.162
  LVESD (mm)                    4.34±0.40             4.19±0.40                                                           4.38±0.41           0.547
  LVEDD (mm)                    6.85±0.47             6.98±0.43                                                           7.26±0.35           0.150
  IVS (mm)                      1.75±0.11             1.64±0.26                                                           1.74±0.16           0.305
  mPAP (mm Hg)                  65.51±2.66            67.88±1.65[\*](#tfn3-medscimonit-26-e918883){ref-type="table-fn"}   66.40±1.41          0.035
  LVEF (%)                      64.77±5.73            69.12±4.48                                                          67.85±9.18          0.236
  Heart weight ratio (1/1000)   3.07±0.07             3.24±0.24                                                           3.16±0.22           0.168

Values are expressed as mean±SD. SBP -- systolic blood pressure; DBP -- diastolic blood pressure; MBP -- mean blood pressure; LAD -- left atrial diameter; LVESD -- left ventricular end-systolic dimension; LVEDD -- left ventricular end-diastolic dimension; IVS -- interventricular septum; mPAP -- mean pulmonary artery pressure; LVEF -- left ventricular ejection fraction;

p\<0.05 *vs.* Control group.

###### 

Surface ECGs and electrophysiological parameters.

                                        Control group (n=10)              CIH group (n=10)                                                                        Doxy group (n=10)                                                                       P value
  ------------------------------------- --------------------------------- --------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------- ---------
  **Surface ECG parameters, ms**                                                                                                                                                                                                                          
  HR, beats per min                     413.98±26.39                      421.07±17.30                                                                            415.72±21.54                                                                            0.757
  PR interval (ms)                      43.63±2.89                        41.89±2.53                                                                              44.37±3.35                                                                              0.174
  P-wave duration (ms)                  14.13±1.78                        18.13±6.22[\*](#tfn5-medscimonit-26-e918883){ref-type="table-fn"}                       15.37±2.09                                                                              0.084
  QRS duration (ms)                     17.33±2.14                        17.13±1.70                                                                              17.07±2.53                                                                              0.962
  QT interval (ms)                      61.83±8.29                        66.14±9.00                                                                              69.85±17.83                                                                             0.369
  QTc interval (ms)                     161.30±19.95                      175.92±23.48                                                                            181.06.32±47.93                                                                         0.391
  Tpeak Tend Interval (ms)              33.11±5.59                        36.53±7.10                                                                              38.99±18.46                                                                             0.546
  **Electrophysiological parameters**                                                                                                                                                                                                                     
   **IACT**                                                                                                                                                                                                                                               
  150 ms                                23.90±2.38                        27.00±2.94 [\*](#tfn5-medscimonit-26-e918883){ref-type="table-fn"}                      23.00±2.05[\#\#](#tfn8-medscimonit-26-e918883){ref-type="table-fn"}                     0.003
  200 ms                                23.40±2.84                        26.40±3.53 [\*](#tfn5-medscimonit-26-e918883){ref-type="table-fn"}                      22.70±2.31[\#\#](#tfn8-medscimonit-26-e918883){ref-type="table-fn"}                     0.021
  250 ms                                23.00±2.45                        27.10±3.14 [\*\*](#tfn6-medscimonit-26-e918883){ref-type="table-fn"}                    22.30±2.50[\#\#](#tfn8-medscimonit-26-e918883){ref-type="table-fn"}                     0.001
  *P* value                             0.736                             0.871                                                                                   0.793                                                                                   
   **HRAERP**                                                                                                                                                                                                                                             
  150 ms                                49.80±3.46                        51.40±1.90                                                                              49.40±4.01                                                                              0.359
  200 ms                                51.00±3.16                        50.20±3.33                                                                              51.60±2.95                                                                              0.614
  250 ms                                51.80±3.05                        49.60±2.95                                                                              51.60±3.10                                                                              0.219
  *P* value                             0.391                             0.354                                                                                   0.262                                                                                   
   **HLAERP**                                                                                                                                                                                                                                             
  150 ms                                52.20±3.71                        50.80±2.53                                                                              51.60±3.50                                                                              0.638
  200 ms                                52.00±2.49                        51.40±3.13                                                                              52.60±2.32                                                                              0.610
  250 ms                                51.20±3.29                        51.80±6.00                                                                              51.00±4.03                                                                              0.921
  *P* value                             0.763                             0.865                                                                                   0.567                                                                                   
  **AF inducibility (burst pacing)**                                                                                                                                                                                                                      
  50 ms                                 2.10/10±1.60/10 (21.00%±15.95%)   3.50/10±1.27/10 (35.00%±12.69)[\*](#tfn5-medscimonit-26-e918883){ref-type="table-fn"}   2.00/10±1.15/10 (20.00%±11.55)[\#](#tfn7-medscimonit-26-e918883){ref-type="table-fn"}   0.034

Values are expressed as mean±SD. IACT -- inter-atrial conduction time; HLAERP -- high left atrium effective refractory period; HRAERP -- high right atrium effective refractory period.

p\<0.05,

p\<0.01 *vs.* Control group (CON).

p\<0.05,

p\<0.01 *vs.* CIH group.
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